Viatris Available For Sale Securities Debt Securities Current increased by 7.1% to $40.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $38.00M to $40.70M. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows relatively stable performance with a 0.8% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $38.20M | $35.30M | $37.00M | $38.00M | $40.70M |
| QoQ Change | — | -7.6% | +4.8% | +2.7% | +7.1% |
| YoY Change | — | -7.6% | +4.8% | +2.7% | +7.1% |